Development of new biomarkers aimed at proper use of antibacterial agents and improvement of prognosis in patients with febrile neutropenia

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07167
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Oita University
• Principal Investigator: Itoh Hiroki 大分大学, 医学部, 教授 (50420641)
• Co-Investigator(Kenkyū-buntansha): 田中 遼大 大分大学, 医学部, 准教授 (30781736)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: MR-proADM / バイオマーカー / 血液悪性腫瘍 / 発熱性好中球減少症

Outline of Final Research Achievements

In this study, we examined the usefulness of mid-regional pro-adrenomedullin (MR-proADM) as a novel biomarker that can diagnose infectious diseases of febrile neutropenia (FN) and predict the prognosis. The subjects of this study were patients with hematopoietic malignancies who underwent hematopoietic stem cell transplantation in the hematology ward of Oita University Hospital. In 22 cases and 24 episodes, plasma MR-proADM concentration was highest on day 16 in the late FN, followed by day 4 in the early FN. The correlation of various parameters was evaluated. The plasma MR-proADM concentration showed a positive correlation with the plasma preseptin concentration only.

Free Research Field

医療薬学

Academic Significance and Societal Importance of the Research Achievements

本検討より、血液悪性腫瘍患者のFN発症後に血漿中MR-proADM濃度が最も高くなる時期が明らかになった。また、血液悪性腫瘍患者におけるFN発症後の血漿中MR-proADM濃度の感染症診断能および予後予測能が明らかとなることで、感染症を診断でき、かつ予後悪化を回避可能なMR-proADM濃度が算出されると期待される。そのため、本研究計画より、将来的に血液悪性腫瘍患者がFNを発症した際の広域抗菌薬による初期経験的治療の可否が血漿中MR-proADM濃度で判断できることが期待され、広域抗菌薬の「不必要使用」の減少に繋がるものと期待される。